1 Treating COVID

Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.

Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.

Antiparasitic Drug Ivermectin Has Remarkable Anti-Cancer Activity.

Ivermectin has been repurposed as highly effective antiviral drug. Sadly, this is being ignored by US Medicine.

Challenge-Rechallenge Data from Switzerland reveals Efficacy of Hydroxyxhloroquine Against Corona Virus.

Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.

It’s been over six weeks since Iowa dropped all state-level COVID restrictions, and surprise, surprise, hospitalized patients are down 54 percent. But if you try to Google this information, all you will see is death, dying, and it must be the end of the world because of COVID, which miraculously seems to be a cure... View Article

Antiparasitic Drug Ivermectin Has Remarkable Anti-Cancer Activity.

In this talk, we will discuss the possible dose of Ivermectin for prophylaxis, during the acute disease, and for the long haulers. We will look at the dosage used by various studies, myself for my patients, and recommended by the physicians at FLCCC.net. Note: this is not a prescription. This material is for the educational purpose only.

Ivermectin Works For COVID-19 - LATEST STUDIES More lectures on drbeen.com Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US Start your free trial - no credit card needed: https://members.drbeen.com/freetrial Original in-vitro study about Ivermectin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/ A study from bangladesh found that Ivermectin + Doxyclyclin significantly reduces mortality and morbidity in COVID-19 patients. https://clinicaltrials.gov/ct2/show/study/NCT04523831 A systemic review of the antiviral activity of Ivermectin https://www.nature.com/articles/s41429-020-0336-z https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext PDF for the above study after it was accepted https://journal.chestnet.org/article/S0012-3692(20)34898-4/pdf Pre-print of the above study https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2 A search of various Ivermectin studies for your reading pleasure https://clinicaltrials.gov/ct2/results?cond=Covid19&term=ivermectin&cntry=&state=&city=&dist= Iota carrageenan and Ivermectin oral drops https://clinicaltrials.gov/ct2/show/results/NCT04425850?term=ivermectin&cond=Covid19&draw=2

This article may be...

Rationale Pre-clinical and autopsy studies have fueled the hypothesis that a dysregulated vascular endothelium might play a central role in the pathogenesis of ARDS and multi-organ failure in COVID-19. Objectives To comprehensively characterize and quantify microvascular alterations in patients with COVID-19. Methods Hospitalized adult patients with moderate-to-severe or critical COVID-19 (n = 23) were enrolled non-consecutively in this prospective, observational, cross-sectional, multi-center study. Fifteen healthy volunteers served as controls. All participants underwent intravital microscopy by sidestream dark field imaging to quantify vascular density, red blood cell velocity (VRBC), and glycocalyx dimensions (perfused boundary region, PBR) in sublingual microvessels. Circulating levels of endothelial and glycocalyx-associated markers were measured by multiplex proximity extension assay and enzyme-linked immunosorbent assay. Measurements and main results COVID-19 patients showed an up to 90% reduction in vascular density, almost exclusively limited to small capillaries (diameter 4–6 µm), and also significant reductions of VRBC. Especially, patients on mechanical ventilation showed severe glycocalyx damage as indicated by higher PBR values (i.e., thinner glycocalyx) and increased blood levels of shed glycocalyx constituents. Several markers of endothelial dysfunction were increased and correlated with disease severity in COVID-19. PBR (AUC 0.75, p = 0.01), ADAMTS13 (von Willebrand factor-cleaving protease; AUC 0.74, p = 0.02), and vascular endothelial growth factor A (VEGF-A; AUC 0.73, p = 0.04) showed the best discriminatory ability to predict 60-day in-hospital mortality. Conclusions Our data clearly show severe alterations of the microcirculation and the endothelial glycocalyx in patients with COVID-19. Future therapeutic approaches should consider the importance of systemic vascular involvement in COVID-19.

Nebulizing Magnesium and other natural medicinals as Iodine, Sodium Bicarbonate, peroxide and glutathione are strong treatment options that deliver the medicinals directly to the tracheobronchial tree.

It is the most controversial word on social media HYDR0X0YCHL0RQUlNE.What is the truth about this drug?  Turns out there was a study done in 2005 that found it could treat another C0R0NAVlRUS known as SARS and there has now been a full peer reviewed study that proves HCQ actually cut the death rate in half.  Watch and share this video before its taken down! Support our new free speech platform https://ISE.Media ---------------- Support Truth in Media by visiting our sponsors: New Free Speech Platform ISE.Media https://ISE.Media Pulse Cellular: Use code "TRUTH" for 10% every plan for life. https://truthinmedia.com/phone Pure VPN: Military grade vpn protection. https://truthinmedia.com/vpn Brave Browser: Open source and built by a team of privacy focused, performance oriented pioneers of the web. https://truthinmedia.com/brave #benswann

There are limited proven therapies for COVID-19. Vitamin C’s antioxidant, anti-inflammatory and immunomodulating effects make it a potential therapeutic candidate, both for the prevention and amelioration of COVID-19 infection, and as an adjunctive therapy in the critical care of COVID-19. This literature review focuses on vitamin C deficiency in respiratory infections, including COVID-19, and the mechanisms of action in infectious disease, including support of the stress response, its role in preventing and treating colds and pneumonia, and its role in treating sepsis and COVID-19. The evidence to date indicates that oral vitamin C (2–8 g/day) may reduce the incidence and duration of respiratory infections and intravenous vitamin C (6–24 g/day) has been shown to reduce mortality, intensive care unit (ICU) and hospital stays, and time on mechanical ventilation for severe respiratory infections. Further trials are urgently warranted. Given the favourable safety profile and low cost of vitamin C, and the frequency of vitamin C deficiency in respiratory infections, it may be worthwhile testing patients’ vitamin C status and treating them accordingly with intravenous administration within ICUs and oral administration in hospitalised persons with COVID-19.

Abstract. More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that numb

Push Health enables doctors, medical providers and patients to connect virtually for concierge telemedicine care

This article may be...

In view of the emerging COVID-19 pandemic caused by SARS-CoV-2 virus, the search for potential protective and therapeutic antiviral strategies is of particular and urgent interest. Zinc is known to modulate antiviral and antibacterial immunity and regulate ...

Ivermectin has been repurposed as highly effective antiviral drug. Sadly, this is being ignored by US Medicine.

Frank Lee, MD's Push Health practice in Allen, TX. Register to get online healthcare services today.

Courageous Doctors quote FDR in 1933 We have Nothing to Fear except Fear itself.

One does not have to be an anti-vaxxer to see and understand that COVID vaccines are not needed. They are not required legally or for any medical or public health reason to treat or prevent COVID-19. There is a broad range of both natural and pharmaceutical treatments widely available, many already proven to be very... View Article